Evidence map›Paper›PMID 35982097›Full record

ArticleScientific reports2022

Efficient engraftment and viral transduction of human hepatocytes in an FRG rat liver humanization model.

Marisa Carbonaro, Jeffrey Lee, Evangelos Pefanis, Mathieu Desclaux, Kehui Wang, Alexander Pennington, Hui Huang, Alejo Mujica, Jose Rojas, Roxanne Ally and 8 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Marisa CarbonaroRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Jeffrey LeeRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Evangelos PefanisRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Mathieu DesclauxRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Kehui WangRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Alexander PenningtonRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Hui HuangRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Alejo MujicaRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Jose RojasRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Roxanne AllyRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Daniel KennedyRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Michael BrownRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Vitaliy RogulinRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Sven Moller-TankRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Leah SabinRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Brian ZambrowiczRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Gavin ThurstonRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Zhe LiRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. zhe.li@regeneron.com.
Regeneron (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Humanized liver rodent models, in which the host liver parenchyma is repopulated by human hepatocytes, have been increasingly used for drug development and disease research. Unlike the leading humanized liver mouse model in which Fumarylacetoacetate Hydrolase (Fah), Recombination Activating Gene (Rag)-2 and Interleukin-2 Receptor Gamma (Il2rg) genes were inactivated simultaneously, generation of similar recipient rats has been challenging. Here, using Velocigene and 1-cell-embryo-targeting technologies, we generated a rat model deficient in Fah, Rag1/2 and Il2rg genes, similar to humanized liver mice. These rats were efficiently engrafted with Fah-expressing hepatocytes from rat, mouse and human. Humanized liver rats expressed human albumin and complement proteins in serum and showed a normal liver zonation pattern. Further, approaches were developed for gene delivery through viral transduction of human hepatocytes either in vivo, or in vitro prior to engraftment, providing a novel platform to study liver disease and hepatocyte-targeted therapies.

Indexed as

HepatocytesLiver DiseasesAnimalsDisease Models, AnimalHumansLiverMiceRats

Identifiers

PMID35982097
PMCPMC9388686
OpenAlexW4292249804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.